Dextran Sulfate and Heparin Combination for Thromboinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for thromboinflammation, such as instant blood-mediated reaction (IBMIR) and ischemia-reperfusion injury (IRI), are inadequate, with dextran sulfate showing superior efficacy over heparin but still requiring enhancement for effective management of thromboinflammatory responses.
Innovation Solution
A combination of dextran sulfate and heparin, where heparin synergistically boosts the anti-thromboinflammatory effects of dextran sulfate, inhibiting platelet binding, coagulation activation, and complement activation, thereby reducing thromboinflammatory parameters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dextran sulfate is used to treat thromboinflammation, then anti-thromboinflammatory effects are improved, but treatment effectiveness is insufficient without additional enhancement
Solution Approach 1:
The patent combines dextran sulfate and heparin into a single therapeutic agent. Dextran sulfate provides strong anti-thromboinflammatory effects by inhibiting platelet binding and coagulation activation, while heparin enhances these effects through synergistic mechanisms including complement activation inhibition. This merging of two substances creates a treatment that is more effective than either substance alone, resolving the contradiction between reliability and productivity.
Solution Approach 2:
The therapeutic combination of dextran sulfate and heparin represents a composite material approach where two distinct substances with different mechanisms of action are combined. Dextran sulfate primarily affects platelet and coagulation pathways, while heparin additionally inhibits complement activation and enhances anticoagulation. This composite therapy achieves superior treatment effectiveness compared to single-agent therapies.
2Reliability
If heparin is used alone to treat thromboinflammation, then anticoagulation is provided, but it is outperformed by dextran sulfate
Solution Approach 1:
The patent merges heparin with dextran sulfate to create a combination therapy. While heparin alone provides anticoagulation, the combination with dextran sulfate enhances overall treatment performance through synergistic effects including improved platelet binding inhibition, enhanced coagulation activation inhibition, and additional complement activation inhibition provided by heparin.
3Productivity
If a combination of dextran sulfate and heparin is used, then synergistic anti-thromboinflammatory effects are achieved, but treatment complexity increases
Solution Approach 1:
The patent combines dextran sulfate and heparin into a single therapeutic regimen that can be administered together. This merging approach achieves synergistic effects that enhance treatment productivity while managing complexity through coordinated administration of the two substances as a unified therapy rather than separate, complex regimens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly reduces platelet binding, coagulation activation, and complement activation, restoring hematological parameters and inhibiting thromboinflammatory responses beyond the effects of either compound alone, demonstrating a synergistic effect in treating thromboinflammation.
Implementation Method 1
dextran sulfate has been shown to be effective in treatment of thromboinflammation... heparin, has also been tested for use in treatment of thromboinflammation
Implementation Method 2
The combination significantly reduces platelet binding, coagulation activation, and complement activation
Implementation Method 3
heparin, was capable of enhancing the inhibitory effect of dextran sulfate... on such complement activation on platelets
Data Source
AI summary
The invention relates to a combination comprising an effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, and an effective amount of heparin, or a pharmaceutically acceptable salt thereof, for use in treatment of thromboinflammation, such as instant blood-mediated inflammatory reaction (IBMIR) and ischemia-reperfusion injury (IRI). The invention is based on the surprising finding that heparin, or the pharmaceutically acceptable salt thereof, can synergistically boost anti-thromboinflammatory effects of dextran sulfate, or the pharmaceutically acceptable salt thereof.